0001209191-22-059883.txt : 20221205 0001209191-22-059883.hdr.sgml : 20221205 20221205195237 ACCESSION NUMBER: 0001209191-22-059883 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20221201 FILED AS OF DATE: 20221205 DATE AS OF CHANGE: 20221205 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Cardama Alfonso Quintas CENTRAL INDEX KEY: 0001760104 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-38811 FILM NUMBER: 221446392 MAIL ADDRESS: STREET 1: C/O TCR2 THERAPEUTICS INC. STREET 2: 100 BINNEY STREET CITY: CAMBRIDGE STATE: MA ZIP: 02142 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: TCR2 THERAPEUTICS INC. CENTRAL INDEX KEY: 0001750019 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 474152751 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 100 BINNEY STREET CITY: CAMBRIDGE STATE: MA ZIP: 02142 BUSINESS PHONE: 617-949-5200 MAIL ADDRESS: STREET 1: 100 BINNEY STREET CITY: CAMBRIDGE STATE: MA ZIP: 02142 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2022-12-01 0 0001750019 TCR2 THERAPEUTICS INC. TCRR 0001760104 Cardama Alfonso Quintas C/O TCR2 THERAPEUTICS 100 BINNEY STREET CAMBRIDGE MA 02142 0 1 0 0 Chief Medical Officer Common Stock 46915 D Common Stock 2022-12-01 4 M 0 95385 A 142300 D Common Stock 2022-12-02 4 S 0 3636 1.39 D 138664 D Restricted Stock Unit 2022-12-01 4 M 0 69025 0.00 A Common Stock 69025 1409 D Restricted Stock Unit 2022-12-01 4 M 0 17545 0.00 A Common Stock 17545 6489 D Restricted Stock Unit 2022-12-01 4 M 0 8815 0.00 A Common Stock 8815 9549 D Represents the the aggregate number of common stock converted from restricted stock units granted to the reporting person on 11/17/2022 pursuant to the issuer's offer to exchange eligible options for new restricted stock units program. Each restricted stock unit represents a right to receive one share of the issuer's common stock at the time of vesting for no consideration. The sales reported represent the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of restricted stock units. These sales were automatic and intended to qualify under Rule 10b5-1. 98% of the restricted stock units vested on December 1, 2022, and the remaining 2% will vest on December 1, 2023. 73% of these restricted stock units vested on December 1, 2022, 25% will vest on December 1, 2023 and the remaining 2% will vest on December 1, 2024. 48% of these restricted stock units vested on December 1, 2022, 25% will vest on December 1, 2023, another 25% will vest on December 1, 2024 and the remaining 2% will vest on December 1, 2025. Margaret Siegel as Attorney-In-Fact 2022-12-05